{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:27:01Z","timestamp":1790404021806,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Dermavant Sciences, Inc"},{"name":"Incyte"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lily"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014005","name":"Actavis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Actelion"},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"name":"Cassiopea"},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"name":"Kadmon Corporation"},{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LEO Pharma"},{"name":"Menlo"},{"name":"Ortho Dermatologics"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jaad.2020.05.135","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T18:49:09Z","timestamp":1591123749000},"page":"632-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis"],"prefix":"10.1016","volume":"84","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.05.135_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","article-title":"A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis","volume":"80","author":"Peppers","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.135_bib2","series-title":"Hurwitz Clinical Pediatric Dermatology","article-title":"Eczematous eruptions in childhood","author":"Paller","year":"2016"},{"key":"10.1016\/j.jaad.2020.05.135_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","article-title":"The burden of atopic dermatitis: impact on the patient, family, and society","volume":"22","author":"Carroll","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2020.05.135_bib4","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","article-title":"Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema","volume":"60","author":"Lewis-Jones","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jaad.2020.05.135_bib5","first-page":"S115","article-title":"Overview of atopic dermatitis","volume":"23","author":"Avena-Woods","year":"2017","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jaad.2020.05.135_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2020.05.135_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.05.135_bib8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2020.05.135_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaci.2016.06.002","article-title":"Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march","volume":"138","author":"Egawa","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2020.05.135_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/imr.12545","article-title":"The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis","volume":"278","author":"Otsuka","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaad.2020.05.135_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.05.135_bib12","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.4049\/jimmunol.175.11.7348","article-title":"Effects of aryl hydrocarbon receptor signaling on the modulation of TH1\/TH2 balance","volume":"175","author":"Negishi","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaad.2020.05.135_bib13","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.05.135_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdermsci.2015.07.011","article-title":"Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor","volume":"80","author":"Furue","year":"2015","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaad.2020.05.135_bib15","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjd.12590","article-title":"Translating\u00a0Patient-Oriented Eczema Measure (POEM) scores\u00a0into clinical practice by suggesting severity strata derived using anchor-based methods","volume":"169","author":"Charman","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.05.135_bib16","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation\u00a0of a new tool for measuring atopic eczema severity from the patients' perspective","volume":"140","author":"Charman","year":"2004","journal-title":"Arch Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220310112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220310112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:56:54Z","timestamp":1759273014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220310112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0190962220310112"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.135","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}